What is Nkarta?
Nkarta is a clinical-stage biotechnology firm specializing in the advancement of allogeneic, off-the-shelf natural killer (NK) cell therapies designed to treat cancer patients. The company distinguishes itself through a unique integration of cell expansion and cryopreservation platforms combined with proprietary cell engineering technologies. This approach allows for the creation of highly efficient manufacturing processes, resulting in cell therapy candidates that are specifically engineered to improve tumor targeting and enhance persistence within the human body. By addressing the limitations of traditional autologous therapies, Nkarta is positioning itself as a leader in the development of scalable, standardized oncology treatments.
How much funding has Nkarta raised?
Nkarta has raised a total of $125M across 2 funding rounds:
Series A
$11M
Series B
$114M
Series A (2015): $11M, investors not publicly disclosed
Series B (2019): $114M led by Samsara BioCapital, Logos Capital, Deerfield Management, NEA Ventures, Amgen Business Development, RA Capital Management, SR One, Novo Holdings, and Life Science Partners
Key Investors in Nkarta
Deerfield Management
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem with flexible funding models.
Amgen Business Development
Amgen Oncology is dedicated to transforming cancer treatment through innovative therapies and a commitment to patient care, focusing on addressing the needs of patients with complex cancers.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing its internal think tank, TechAtlas, to support investment strategies.
What's next for Nkarta?
With the support of its recent financing, Nkarta is well-positioned to transition its lead candidates further through the clinical pipeline. The strategic focus remains on optimizing the manufacturing of its off-the-shelf NK cell products to ensure consistent quality and efficacy. As the company moves forward, the emphasis will likely shift toward expanding its clinical trial footprint and refining its engineering technologies to address a broader range of complex cancer indications. The continued backing from specialized life science investors provides the operational runway necessary to navigate the complexities of late-stage clinical development and potential commercialization pathways.
See full Nkarta company page
